SBIR-STTR Award

Fluorophore Carbohydrate Test--Lysosomal Storage Disease
Award last edited on: 6/1/09

Sponsored Program
SBIR
Awarding Agency
NIH : NICHD
Total Award Amount
$636,671
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Christopher Starr

Company Information

Glyko Inc

1933 Davis St, Suite 207
San Leandro, CA 94577
   (510) 638-6900
   jowegstein@prozyme.com
   www.prozyme.com
Location: Single
Congr. District: 13
County: Alameda

Phase I

Contract Number: 1R443HD33622-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1995
Phase I Amount
$66,571
The thirty known types of Lysosomal Storage Diseases (LSDs) collectively represent over 15% of all known inborn errors of metabolism. The clinical indications of disease which include peripheral and CNS disorders, mental retardation, skeletal defects and early childhood death are a result of the accumulation of incompletely degraded complex carbohydrates and glycolipids in the cell. These incompletely degraded carbohydrates are excreted into the urine and the amount and type of excreted carbohydrate can be used as diagnostic "markers" for the type of storage disease. The routine screening assays for LSDs used by most clinical reference laboratories are insensitive, non-standardized procedures, where disease identification is highly subjective. We have developed a highly sensitive and reliable method for identifying and quantifying urinary oligosaccharides based on fluorescence-assisted-carbohydrate- electrophoresis or FACE. Currently, the FACE assay is being evaluated in the clinical laboratory as a method to identify children with oligosaccharidoses-type LSDs. This proposal outlines the development of a similar FACE assay which should result in a relatively easy and reliable test for mucopolysaccharidoses-type LSDs in children.National Institute of Child Health and Human Development (NICHD)

Phase II

Contract Number: 2R44HD33622-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1997
Phase II Amount
$570,100
The thirty known types of Lysomomal Storage Diseases (LSDs) collectively represent over 15% of all known inborn errors of metabolism. The clinical indications of disease which include peripheral and CNS disorders, mental retardation, skeletal defects and early childhood death are a result of the accumulation of incompletely degraded complex carbohydrates and glycolipids in the cell. These incompletely degraded carbohydrates are excreted into the urine and the amount and type of excreted carbohydrate can be used as diagnostic "markers" for the type of storage disease. The routine screening assays for LSDs used by most clinical reference laboratories are insensitive, non-standardized procedures, where disease identification is highly subjective. We have developed a highly sensitive and reliable method for identifying and quantifying urinary oligosaccharides based on fluorescence-assisted-carbohydrate- electrophoresis or FACE. Currently, the FACE assay is being evaluated in the clinical laboratory as a method to identify children with oligosaccharidoses-type LSDs. This proposal outlines the development of a similar FACE assay which should result in a relatively easy and reliable test for mucopolysaccharidoses-type LSDs in children.Proposed commercial application:This research will result in the commercial development of the first comprehensive system for routine LSD screening. The system will include reagent kits consisting of quality controlled fluorescent dyes, buffers, standards and controls; precast polyacrylamide gels, and complete manuals containing standardized and tested protocols for routine LSD screening. A complete CCD-based gel imaging system with neural network pattern recognition software will also be commercialized to aid in disease identification, data analysis and data archiving.Thesaurus termsfluorescent dye /probe, gel electrophoresis, inborn lysosomal enzyme disorder, inborn metabolism disorder diagnosis, ionophore, method development, urinalysis biotechnology, carbohydrate, immunofluorescence technique, mucopolysaccharide, mucopolysaccharidosis gel mobility shift assayNational Institute of Child and Human Development (NICHD)